---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-26-000018"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:50:07.879905+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agios outlines 2026 milestones: AQVESME launch in thalassemia, potential sNDA for sickle cell disease

## Summary
- AQVESME (mitapivat) U.S. approval in thalassemia Dec 2025; commercial launch underway, product available late Jan 2026.
- Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026; U.S. submission to follow.
- Pipeline: tebapivat Phase 2 sickle cell topline H2 2026; Phase 2b LR-MDS topline H1 2026.
- AG-236 (siRNA for PV) Phase 1 healthy volunteer topline H1 2026; AG-181 Phase 1b PKU trial init H1 2026.
- Target >$1B peak global sales from existing thalassemia and PK deficiency commercial presence.

## SEC filing metadata
- accession: 0001439222-26-000018
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/0001439222-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000018/agio-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-26-000018
- JSON: https://secwatch.observer/filing/0001439222-26-000018.json
- Plain text: https://secwatch.observer/filing/0001439222-26-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.